| Literature DB >> 21873946 |
Dorota M Olszewska-Słonina1, Dariusz Mątewski, Rafał Czajkowski, Krzysztof J Olszewski, Alina Woźniak, Grażyna Odrowąż-Sypniewska, Kinga Lis, Dariusz Musiałkiewicz, Bogna Kowaliszyn.
Abstract
BACKGROUND: The aim of this study was to evaluate the concentration of malondialdehyde (MDA) in erythrocytes and in blood plasma and the activity of blood paraoxonase (PON1) of patients with osteoarthrosis (OA) submitted to endoprosthesis implantation for evaluating oxidative stress. MATERIAL/Entities:
Mesh:
Substances:
Year: 2011 PMID: 21873946 PMCID: PMC3560525 DOI: 10.12659/msm.881936
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Characteristics of study groups.
| Number | Percent | Age [years]
| |||
|---|---|---|---|---|---|
| Mean | SD | Min-Max | |||
| 55 | 100.0 | 63.91 | 10.73 | 40–78 | |
| Gender | |||||
| Women | 36 | 65.5 | 66.47 | 9.94 | 46–78 |
| Men | 19 | 34.5 | 59.05 | 10.75 | 40–77 |
| Age group | |||||
| <69 | 31 | 56.4 | 56.39 | 8.164 | 40–69 |
| >70 | 24 | 43.6 | 73.63 | 2.96 | 70–78 |
| 57 | 100.0 | 62.96 | 14.57 | 24–90 | |
| Gender | |||||
| Women | 29 | 50.9 | 64.03 | 14.63 | 24–90 |
| Men | 28 | 49.1 | 61.86 | 14.68 | 32–89 |
| Age group | |||||
| <69 | 36 | 63.2 | 54.47 | 10.89 | 24–69 |
| >70 | 21 | 36.8 | 77.52 | 5.84 | 70–90 |
Figure 1Level of malondialdehyde in erythrocytes (MDAe), malondialdehyde in blood plasma (MDA) and activity of paraoxonase 1 (PON1) in blood serum of patients with osteoarthrosis (studied group) and in the control group.
Level of malondialdehyde in erythrocytes (MDAe), malondialdehyde in blood plasma (MDA) and activity of paraoxonase I (PON1) in blood serum of patients with osteoarthrosis (studied group) and in the control group.
| Osteoarthrosis group (n=55) | Control group (n=57) | |||||
|---|---|---|---|---|---|---|
| Before surgery | 10 days after surgery | Mean ±SD | Min–Max | |||
| Mean ±SD | Min–Max | Mean ±SD | Min–Max | |||
| MDAe [nmol/g Hb] | 49.75±23.98 | 19.51–206.99 | 42.37±20.33 | 9.23–161.00 | 40.24±13.81 | 22.86–86.99 |
| MDA [nmol/ml] | 0.48±0.11 | 0.19–0.74 | 0.52±0.13 | 0.31–0.84 | 0.54±0.14 | 0.26–0.90 |
| PON1 [U/l] | 116.62±41.58 | 33.99–269.71 | 113.30±51.59 | 22.85–369.14 | 61.83±30.61 | 12.52–200.59 |
Statistically significant as compared to a control group
p<0.01. Statistically significant as compared to a studied group before surgery
p< 0.01.
Level of malondialdehyde in erythrocytes (MDAe), malondialdehyde in blood plasma (MDA) and activity of paraoxonase (PON1) in blood serum of men and women with osteoarthrosis (studied groups) and in the control groups.
| Osteoarthrosis men group (n=19) | Control men group (n=28) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before surgery | 10 days after surgery | Mean | SD | Min–Max | |||||
| Mean | SD | Min–Max | Mean | SD | Min–Max | ||||
| MDAe [nmol/g Hb] | 64.42 | 29.53 | 23.98–206.99 | 45.38 | 17.74 | 23.45–92.46 | 42.58 | 17.08 | 22.86–86.99 |
| MDA [nmol/ml] | 0.48 | 0.12 | 0.19–0.69 | 0.53 | 0.14 | 0.31–0.84 | 0.55 | 0.15 | 0.26–0.88 |
| PON1 [U/l] | 119.54 | 40.19 | 40.53–193.70 | 97.60 | 40.11 | 22.85–178.20 | 64.60 | 30.72 | 12.52–200.59 |
| MDAe [nmol/g Hb] | 41.44 | 16.73 | 19.51–89.64 | 40.50 | 17.79 | 9.23–161.00 | 37.98 | 9.45 | 23.08–54.89 |
| MDA [nmol/ml] | 0.49 | 0.11 | 0.25–0.74 | 0.51 | 0.11 | 0.32–0.79 | 0.53 | 0.14 | 0.33–0.90 |
| PON1 [U/l] | 115.12 | 42.77 | 33.99–269.71 | 123.39 | 60.99 | 38.23–369.14 | 59.05 | 23.93 | 26.41–126.76 |
Statistically significant as compared to a control group
p< 0.05;
p< 0.01. Statistically significant as compared to a studied group before surgery
p<0.01;
p<0.05.
Level of malondialdehyde in erythrocytes (MDAe), malondialdehyde in blood plasma (MDA) and activity of paraoxonase (PON1) in blood serum of OA patients under 69 years and over 70 year (studied groups) and in the control groups.
| Studied group of <69 years (n=31) | Control group of <69 year olds (n=36) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before surgery | 10 days after surgery | Mean | SD | Min–Max | |||||
| Mean | SD | Min–Max | Mean | SD | Min–Max | ||||
| MDAe [nmol/g Hb] | 47.86** | 19.85 | 19.51–171.36 | 41.31 | 19.02 | 9.23–93.46 | 39.82 | 13.29 | 23.08–86.99 |
| MDA [nmol/ml] | 0.48* | 0.12 | 0.19–0.72 | 0.51 | 0.14 | 0.31–0.84 | 0.55 | 0.16 | 0.26–0.90 |
| PON1 [U/l] | 117.20* | 43.65 | 33.99–269.71 | 105.83*,# | 42.76 | 53.04–247.89 | 66.76 | 32.58 | 12.52–200.59 |
| MDAe [nmol/g Hb] | 52.30* | 19.54 | 23.98–206.99 | 43.93**,# | 21.08 | 9.93–161.00 | 40.97 | 14.98 | 22.86–79.69 |
| MDA [nmol/ml] | 0.49 | 0.11 | 0.32–0.74 | 0.53 | 0.10 | 0.32–0.71 | 0.53 | 0.12 | 0.33–0.81 |
| PON1 [U/l] | 115.86* | 39.66 | 40.53–193.70 | 124.91*,## | 53.09 | 22.85–369.14 | 52.95 | 22.00 | 24.00–112.98 |